Literature DB >> 9210696

In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori.

J M Meyer1, S Ryu, S L Pendland, L H Danziger.   

Abstract

The activity of clarithromycin-14-hydroxyclarithromycin (2:1 ratio) and bismuth subsalicylate or amoxicillin against Helicobacter pylori was determined by the checkerboard technique in vitro. Clarithromycin-14-hydroxyclarithromycin and amoxicillin resulted in additive effects in 7 of 22 isolates, compared to 14 of 22 isolates when bismuth subsalicylate was substituted for amoxicillin. Synergy was not demonstrated and is probably not responsible for the clinical success of treatment combinations containing clarithromycin.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9210696      PMCID： PMC163970     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  The susceptibility of Campylobacter pylori to antiulcer agents and antibiotics.

Authors:  T Nagate; K Numata; K Hanada; I Kondo
Journal:  J Clin Gastroenterol       Date:  1990       Impact factor: 3.062

2.  The minimum inhibitory concentrations of various bismuth salts against Campylobacter pylori.

Authors:  K Vogt; M Warrelmann; H Hahn
Journal:  Zentralbl Bakteriol       Date:  1989-09

3.  Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.

Authors:  D J Hardy; R N Swanson; R A Rode; K Marsh; N L Shipkowitz; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

4.  In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori).

Authors:  D L Van Caekenberghe; J Breyssens
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

5.  Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxyclarithromycin.

Authors:  W W Hoover; M S Barrett; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1992 Mar-Apr       Impact factor: 2.803

Review 6.  Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology.

Authors:  A H Soll
Journal:  JAMA       Date:  1996-02-28       Impact factor: 56.272

7.  The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis.

Authors:  C S Goodwin; P Blake; E Blincow
Journal:  J Antimicrob Chemother       Date:  1986-03       Impact factor: 5.790

8.  Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori.

Authors:  G Cederbrant; G Kahlmeter; C Schalén; C Kamme
Journal:  J Antimicrob Chemother       Date:  1994-12       Impact factor: 5.790

9.  Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones.

Authors:  D J Hardy; C W Hanson; D M Hensey; J M Beyer; P B Fernandes
Journal:  J Antimicrob Chemother       Date:  1988-11       Impact factor: 5.790
  9 in total
  4 in total

1.  In vitro activities of a new ketolide, ABT-773, alone and in combination with amoxicillin, metronidazole, or tetracycline against Helicobacter pylori.

Authors:  S L Pendland; J L Prause; M M Neuhauser; N Boyea; J M Hackleman; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

2.  Competition of various beta-lactam antibiotics for the major penicillin-binding proteins of Helicobacter pylori: antibacterial activity and effects on bacterial morphology.

Authors:  C R DeLoney; N L Schiller
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

3.  Activities of beta-lactams and macrolides against Helicobacter pylori.

Authors:  I J Hassan; R M Stark; J Greenman; M R Millar
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

4.  Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects.

Authors:  Woo Yul Lee; EunSil Oh; Mengqi Cui; Choon Ok Kim; Yeji Lim; Hunam Kim; Hyeonsoo Park; Sukyong Yoon; Min Soo Park; Taegon Hong
Journal:  Transl Clin Pharmacol       Date:  2020-03-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.